Lyophilised Oxalobacter formigenes - OxThera AB

Drug Profile

Lyophilised Oxalobacter formigenes - OxThera AB

Alternative Names: IxOC 3; Lyophylised Oxalobacter formigenes; OC 3; OC5; Oxabact; Oxalobacter formigenes product - OxThera AB

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ixion Biotechnology
  • Developer OxThera
  • Class Bacteria; Probiotics
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria; Short bowel syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Primary hyperoxaluria
  • Clinical Phase Unknown Short bowel syndrome

Most Recent Events

  • 07 Apr 2017 OxThera plans a phase III trial for Primary hyperoxaluria (NCT03116685)
  • 29 Nov 2016 OxThera plans a phase III trial for Primary hyperoxaluria in USA and European union
  • 18 Jun 2015 Lyophilised Oxalobacter formigenes is still in phase II/III development for Primary hyperoxaluria in France, Germany, Netherlands, USA and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top